| Aug 7 |
Compugen Ltd. (NASDAQ:CGEN): When Will It Breakeven?
|
| Aug 6 |
Compugen (CGEN) Reports Q2 Loss, Tops Revenue Estimates
|
| Aug 6 |
Compugen: Q2 Earnings Snapshot
|
| Aug 6 |
Compugen GAAP EPS of -$0.02, revenue of $6.7M
|
| Aug 6 |
Compugen Reports Second Quarter 2024 Results
|
| Aug 5 |
Compugen Q2 2024 Earnings Preview
|
| Jul 30 |
Compugen receives FDA approval for Phase I trial of solid tumour treatment
|
| Jul 29 |
Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors
|
| Jul 23 |
Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024
|
| Jul 16 |
Lexeo (LXEO) Down Despite Upbeat Rare Disease Gene Therapy Data
|
